Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Innovent Biologics announced the results of a Phase 1 study of pemigatinib in Chinese patients with advanced solid tumors at the ASCO Annual Meeting 2021. The study included 12 patients from various cancer types who failed prior treatments. The most common adverse events were manageable, with no deaths linked to treatment. Among the 11 evaluable patients, there was a 16.7% objective response rate and a 41.7% disease control rate. Innovent is preparing a New Drug Application for pemigatinib in China, aiming to expand its use beyond FGFR2 mutations.
- Phase 1 study results show manageable safety profile of pemigatinib.
- Objective response rate of 16.7% in evaluable patients indicates potential efficacy.
- Innovent is preparing a New Drug Application for pemigatinib in China, signaling commitment to market entry.
- Only 2 out of 11 patients achieved partial responses, indicating limited initial efficacy.
SAN FRANCISCO and SUZHOU, China, June 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 1 study in Chinese patients with advanced solid tumors were released today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2021.
This is a Phase 1 study to evaluate the pharmacokinetic (PK), pharmacodynamic (PD) and safety of pemigatinib in Chinese patients (pts) with advanced malignancy. Moreover, potential efficacy of pemigatinib was explored in a broad spectrum of fibroblast growth factor receptor (FGFR) alteration in variety of cancer types. 12 patients with 5 different cancer types (colorectal cancer, gastric cancer, cholangiocarcinoma, esophageal carcinoma and breast cancer) and FGF/FGFR1-3 alterations were enrolled. All the subjects were failed to prior standard therapy. As of Jan 31, 2021, all patients received at least once treatment, the safety was controllable with the most common treatment related adverse events (TRAE) of hyperphosphatemia, decreased appetite and diarrhea. Two patients reported ≥ grade 3 TRAEs, which were hyponatremia and proteinuria. There were no TEAEs leading to death or treatment discontinuation. Among 11 efficacy evaluable patients, 2 of them had partial responses (PR) as evaluated by investigators with 1 cholagiocarcinoma harboring FGFR2 point mutation (p.F276C) and the other esophageal carcinoma carrying FGFR1 mutation (p.A354V). 3 patients had a best overall response of stable disease (SD). The objective response rate (ORR) was
Professor Yi Ba from Tianjin Medical University Cancer Institute and Hospital said," Pemigatinib had an acceptable and manageable toxicity in Chinese patients with advanced malignancy. A significant implication of the data is that it extended the population that potentially benefit from pemigatinib other than FGFR2 fusion/rearrangement."
"Several FGFR inhibitors are being in clinical stage" said Dr. Hui Zhou, Senior Vice President of Clinical Development, Innovent Biologics. "Innovent has multiple clinical trials of pemigatinib for the treatment of cholangiocarcinoma and other types of tumors. Currently we are preparing the New Drug Application (NDA) of pemigatinib in China. We presented the data at the ASCO Annual Meeting, which highlighted our capability of small molecules. In the future, we will conduct in-depth clinical development of pemigatnib to explore its treatment in other indications. We are looking forward to providing innovative therapies for more cancer patients in the future."
About Pemazyre® (pemigatinib)
In April 2020, the U.S. Food and Drug Administration (FDA) approved Incyte's Pemazyre® (pemigatinib), a selective, oral inhibitor of FGFR isoforms 1, 2 and 3, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer with a FGFR2 fusion gene, worsening after cancer chemotherapy. In Europe, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Pemazyre is marketed by Incyte in the United States, Europe and Japan.
In December 2018, Innovent and Incyte entered into a strategic collaboration for three clinical-stage product candidates discovered and developed by Incyte, including pemigatinib (FGFR1/2/3 inhibitor). Under the terms of the agreement, Innovent has received the rights to develop and commercialize the three assets in Mainland China, Hong Kong, Macau and Taiwan.
Pemazyre is a trademark of Incyte Corporation.
About Innovent
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, autoimmune, metabolic diseases, and other major therapeutic areas. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. By leveraging this platform, the company has built a robust pipeline of 24 valuable assets in major therapeutic areas, with 4 products officially approved for marketing in China - TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection) and HALPRYZA® (rituximab biosimilar injection), one Biologics License Application (BLA) submission for sintilimab accepted by the U.S. FDA, six assets in Phase 3 or pivotal clinical trials, and 14 more molecules in clinical trials. TYVYT® (sintilimab injection) was included in the National Reimbursement Drug List (NRDL) in 2019 as the historically first PD-1 inhibitor entering in NRDL and the only PD-1 included in the list in that year.
Innovent has built an international team of advanced talented professionals in high-end biopharmaceutical development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China's biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content:http://www.prnewswire.com/news-releases/innovent-releases-phase-1-results-of-pemigatinib-in-chinese-patients-with-advanced-solid-tumors-at-asco-annual-meeting-2021-301306431.html
SOURCE Innovent Biologics, Inc.
FAQ
What were the results of the Phase 1 study of pemigatinib presented at ASCO 2021?
What is pemigatinib's target population according to the study?
What are the next steps for pemigatinib after the ASCO presentation?
How many patients were involved in the Phase 1 pemigatinib study?
What was the safety profile of pemigatinib in the study?
